Analysts' Revenue Estimates For Cellectis S.A. (EPA:ALCLS) Are Surging Higher

Cellectis S.A. (EPA:ALCLS) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The consensus estimated revenue numbers rose, with their view now clearly much more bullish on the company's business prospects. The stock price has risen 4.8% to €11.99 over the past week, suggesting investors are becoming more optimistic. Whether the upgrade is enough to drive the stock price higher is yet to be seen, however.

Following the upgrade, the current consensus from Cellectis' nine analysts is for revenues of US$87m in 2021 which - if met - would reflect a huge 48% increase on its sales over the past 12 months. Before the latest update, the analysts were foreseeing US$79m of revenue in 2021. It looks like there's been a clear increase in optimism around Cellectis, given the decent improvement in revenue forecasts.

View our latest analysis for Cellectis

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Cellectis' past performance and to peers in the same industry. One thing stands out from these estimates, which is that Cellectis is forecast to grow faster in the future than it has in the past, with revenues expected to display 120% annualised growth until the end of 2021. If achieved, this would be a much better result than the 1.1% annual decline over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in the industry are forecast to see their revenue grow 31% per year. Not only are Cellectis' revenues expected to improve, it seems that the analysts are also expecting it to grow faster than the wider industry.

The Bottom Line

The most important thing to take away from this upgrade is that analysts lifted their revenue estimates for this year. The analysts also expect revenues to grow faster than the wider market. Given that analysts appear to be expecting substantial improvement in the sales pipeline, now could be the right time to take another look at Cellectis.

Want more information? We have analyst estimates for Cellectis going out to 2023, and you can see them free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.

When trading Cellectis or any other investment, use the platform considered by many to be the Professional's Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
^*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.